Loading
MDM4 (MDM4 regulator of p53) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 1 more.
Contributes to p53/TP53 regulation. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding their transcriptional activation domains. Inhibits degradation of MDM2.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Nivolumab, Pembrolizumab and Atezolizumab. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes affected pathway 0.57, literature 0.99, genetic association 0.60, somatic mutation 0.97, animal model 0.49).
In plain words · MDM4 (MDM4 regulator of p53) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 1 more.
MDM4 (MDM4 regulator of p53) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 1 more.
Contributes to p53/TP53 regulation. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding their transcriptional activation domains.
No product in this corpus aims at MDM4 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA MDM4: RNA low tissue specificity; high antibody staining in 23 normal tissues; highest cancer staining ovarian cancer (10 of 11 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Breast cancer (all types), Prostate cancer); Open Targets associates it with 1 specific cancer type at or above 0.5 (prostate carcinoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas MDM4 tissue; Open Targets ENSG00000198625 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Shvarts et al, Genomics, 1997, "Isolation and identification of the human homolog of a new p53-binding protein, Mdmx". Source.
Sources: HGNC HGNC:6974 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O15151 (protein name, function text, keywords and locations (REST API)); CIViC gene MDM4 (2 evidence items, 0 assertions, 2 variants; diseases: Cancer (GraphQL API, CC0)); Open Targets ENSG00000198625 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: prostate cancer 0.55, melanoma 0.59, skin cancer 0.56, breast cancer 0.55 (GraphQL API, CC0))
Contributes to p53/TP53 regulation. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding their transcriptional activation domains. Inhibits degradation of MDM2. Can reverse MDM2-targeted degradation of TP53 while maintaining suppression of TP53 transactivation and apoptotic functions. Location: Nucleus; Cytoplasm (UniProt). Locus 1q32.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adipose tissue, Appendix, Breast, Caudate, Epididymis, Esophagus, Gallbladder, Heart muscle.
Medium only: head and neck cancer, prostate cancer, testis cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MDM4" OR ABSTRACT:"MDM4" OR TITLE:"MDM4 regulator of p53" OR ABSTRACT:"MDM4 regulator of p53") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MDM4, not a curated reading list.
Shares The p53 network (guardian of the genome), CIViC, Breast cancer (all types), Open Targets Platform.
Shares The p53 network (guardian of the genome), Skin cancer (all types), CIViC, Breast cancer (all types).
Shares The p53 network (guardian of the genome), CIViC, Breast cancer (all types), Open Targets Platform.
Shares The p53 network (guardian of the genome), Skin cancer (all types), CIViC, Open Targets Platform.